SCLC: second-line therapy with lurbinectedin and doxorubicin on trial

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2023年 / 77卷 / 10期
关键词：
D O I：
10.1055/a-2038-6751
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lurbinectedin ist ein synthetischer Wirkstoff, der die onkogene Transkription des Erbguts hemmt und von der amerikanischen Arzneimittelbehorde FDA eine Zulassung zur Zweitlinientherapie bei kleinzelligem Bronchialkarzinom (SCLC) erhalten hat. Aix et al. wollten nun Sicherheit und Wirksamkeit der Kombination aus Lurbinectedin und Doxorubicin als Zweitlinientherapie bei SCLC prufen und haben eine Phase-III-Studie durchgefuhrt.
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer
    Di Legge, Alessia
    Trivellizzi, Ilaria Nausica
    Moruzzi, Maria Cristina
    Pesce, Adele
    Scambia, Giovanni
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (08) : 1446 - 1451
  • [32] Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial
    Forster, M.
    Moreno, V.
    Calvo, E.
    Olmedo, M. E.
    Lopez-Criado, M. P.
    Lopez-Vilarino, J.
    Nunez, R.
    Kahatt, C.
    Soto-Matos, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S581 - S581
  • [33] Phase II Trial of Apatinib Plus Chemotherapy for Second-Line and Above Treatment of Advanced SCLC: Focus on Efficacy and Safety
    Ma, K.
    Xu, Y.
    Wang, X.
    Cai, Y.
    Sun, C.
    Guo, Y.
    Qiu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S539 - S539
  • [34] Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)
    von Pawel, J.
    Jotte, R.
    Spigel, D. R.
    Socinski, M. A.
    O'brien, M. E. R.
    Pashold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J.
    Nackaerts, K.
    Trigo, J. M.
    Clingan, P.
    Schuette, W.
    Lorigan, P. C.
    Reck, M.
    Domine, M.
    Shepard, F. A.
    Mcnally, R.
    Renschler, M. F.
    ONKOLOGIE, 2011, 34 : 122 - 124
  • [35] Second-Line Biologic Therapy After Vedolizumab
    Ritter, Timothy E.
    Fourment, Chris
    Kuten, Samantha A.
    Hardin, Thomas C.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S429 - S430
  • [36] Second-line therapy for metastatic colorectal cancer
    Price, Timothy J.
    LANCET ONCOLOGY, 2015, 16 (05): : 476 - 477
  • [37] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [38] Consequences of targeted treatments for second-line therapy
    De Maio, E.
    Tibaldi, C.
    D'Incecco, A.
    Bursi, S.
    Barbara, C.
    Cupini, S.
    Di Marsico, R.
    D'Arcangelo, M.
    Landi, L.
    Minuti, G.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 234 - 240
  • [39] Second-line Therapy for Type 2 Diabetes
    Krome, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (19) : 1127 - 1128
  • [40] Budesonide as second-line therapy for microscopic colitis
    Randall, Charles
    Taboada, Carlo
    Gossen, Gary
    Havranek, Russell
    Fincke, Christopher
    Adame, Rodrigo
    Villarreal, Alejandro
    Rendon, Luis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S426 - S426
12345